Cidara Therapeutics (CDTX) Earnings Date, Estimates & Call Transcripts $25.71 +0.33 (+1.30%) As of 03:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Cidara Therapeutics Earnings Summary Cidara Therapeutics posted Q1 2025 earnings on May 8, 2025, reporting an EPS of -$1.66, which beat analysts' consensus estimates of -$5.45 by $3.79. With a trailing EPS of -$29.47, Cidara Therapeutics' earnings are expected to decrease next year, from ($8.74) to ($14.39) per share. Upcoming Q2 Earnings DateAug. 11After Market ClosesEstimatedConsensus EPS (May. 8) -$5.45 Actual EPS (May. 8) -$1.66 Beat By $3.79 Q1 2025 Earnings ResourcesQ1 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)CDTX Upcoming EarningsCidara Therapeutics' next earnings date is estimated for Monday, August 11, 2025, based on past reporting schedules. Powered by Get Cidara Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cidara Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCDTX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CDTX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Cidara Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$5.45-$5.45-$5.45Q2 20251-$1.08-$1.08-$1.08Q3 20251-$0.69-$0.69-$0.69Q4 20251-$1.34-$1.34-$1.34 Cidara Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/11/2025(Estimated)--------5/8/2025Q1 2025-$5.45-$1.66+$3.79-$1.66--3/6/2025Q4 2024-$5.28-$5.38 -$0.10-$5.37--8/13/2024Q2 2024-$3.94-$2.05+$1.89$15.89-$0.30M5/15/2024Q4 2023 -$1.50-$2.28 -$0.78-$2.28$14.50M$8.46M4/22/2024Q4 2023 --$0.80 -$0.80-$0.80-$17.58M11/2/2023Q3 2023 -$2.80-$1.80+$1.00-$0.09$8.02M$12.72M8/3/2023Q2 2023 -$1.60-$2.80 -$1.20-$0.14$14.34M$7.61M Cidara Therapeutics Earnings - Frequently Asked Questions When is Cidara Therapeutics's earnings date? Cidara Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 11th, 2025 based off last year's report dates. Learn more on CDTX's earnings history. Did Cidara Therapeutics beat their earnings estimates last quarter? In the previous quarter, Cidara Therapeutics (NASDAQ:CDTX) reported ($1.66) earnings per share (EPS) to beat the analysts' consensus estimate of ($5.45) by $3.79. Learn more on analysts' earnings estimate vs. CDTX's actual earnings. How can I listen to Cidara Therapeutics's earnings conference call? The conference call for Cidara Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Cidara Therapeutics's conference call transcript? The conference call transcript for Cidara Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Cidara Therapeutics generate each year? Cidara Therapeutics (NASDAQ:CDTX) has a recorded annual revenue of $302,000.00. How much profit does Cidara Therapeutics generate each year? Cidara Therapeutics (NASDAQ:CDTX) has a recorded net income of -$22.93 million. CDTX has generated -$29.47 earnings per share over the last four quarters. What is Cidara Therapeutics's EPS forecast for next year? Cidara Therapeutics's earnings are expected to decrease from ($8.74) per share to ($14.39) per share in the next year. More Earnings Resources from MarketBeat Related Companies AUPH Earnings Date CVAC Earnings Date MLYS Earnings Date PAHC Earnings Date RCUS Earnings Date WVE Earnings Date SNDX Earnings Date COLL Earnings Date ELVN Earnings Date SYRE Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal This page (NASDAQ:CDTX) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the sa...Crypto 101 Media | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsA major regulatory shift is scheduled to take effect this July — and it could have serious implications for yo...Monetary Gold | Sponsored“Biggest Social Security Change Ever”The Financial Times called this new Trump initiative "a big pot of money for the American people." And The Mot...InvestorPlace | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump’s Secret WeaponThe Trump-Elon War Could Trigger an Economic Collapse - Here's Your Only Safe Exit This isn't just a war of...American Alternative | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.It could very well mark the beginning of a new multitrillion-dollar industrial revolution. Up until now, we...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
